Unlocking the Promise of Genome Editing to DeliverĀ Life-Changing Medicines

Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.

Read More

Spotlight

Editas News

December 1, 2014
Editas Medicine Licenses Genome Editing Technology from Massachusetts General Hospital Read More

December 1, 2014
Editas Medicine Licenses Genome Editing Technology from Duke University Read More

December 1, 2014
Editas Medicine Licenses Genome Editing Technology from Broad Institute and Harvard University Read More

September 22, 2014
FierceBiotech names Editas Medicine as one of its Fierce 15 Biotech Companies of 2014 Read More

June 24, 2014
Editas Medicine Appoints Katrine S. Bosley to Chief Executive Officer Read More

May 14, 2014
2014 NEVY Awards: Editas Medicine Wins Hottest Healthcare Startup Read More

April 25, 2014
Editas Medicine Co-founders Present Novel Methods for Improving Genome Editing Specificity in Two Nature Biotechnology Papers Read More

Publications

December 10, 2014
NCBI: Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex.     Read More

October 30, 2014
Nature Biotechnology: Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo.   Read More

October 19, 2014
Nature Biotechnology: In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9.     Read More

October 9, 2014
Cell: CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling.        Read More

September 28, 2014
Nature: Programmable RNA recognition and cleavage by CRISPR/Cas9.   Read More

August 11, 2014
Nature Methods: Improved vectors and genome-wide libraries for CRISPR screening.     Read More

July 1, 2014
Bioinformatics: Genome editing assessment using CRISPR Genome Analyzer (CRISPR-GA).   Read More